Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445307 | 0.69 | — | — | |
| SCHEMBL3082762 | 0.68 | NPC1 (0.42) | CHRM1NPC1RAB9AMDM2CYP1A2 | |
| SCHEMBL6210756 | 0.65 | NPC1 (0.33) | CHRM1NPC1RAB9AMDM2CYP1A2 | |
| SCHEMBL1169059 | 0.64 | KDM4E (0.34) | CHRM1NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL8050156 | 0.63 | CHRM1 (0.34) | CHRM1NPC1RAB9AMDM2CYP1A2 | |
| SCHEMBL15961413 | 0.63 | CHRM1 (0.34) | CHRM1NPC1RAB9AMDM2CYP1A2 | |
| SCHEMBL115772 | 0.62 | NPC1 (0.34) | NPC1RAB9AMDM2 | |
| SCHEMBL11192712 | 0.62 | GSK3B (0.54) | NPC1RAB9ACYP1A2CYP19A1CYP2C9 | |
| SCHEMBL4059081 | 0.62 | CYP1A2 (0.57) | CHRM1NPC1RAB9AMDM2CYP1A2 | |
| SCHEMBL4794205 | 0.61 | CYP1A2 (0.30) | CHRM1NPC1RAB9ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023844-B2 | Heterocyclylpyri (mi) dinylpyrazole as fungicidals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20140256677-A1 | HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | claimed |
| EP-2763987-A1 | HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS | Bayer Intellectual Property GmbH (DE) | 2014-08-13 | — | — | EP | claimed |
| WO-2013050437-A1 | HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-11 | — | — | WO | claimed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3294747-B1 | RUTHENIUM COMPLEXES, METHOD OF PRODUCING THEM, AND THEIR USE | UNIV WARSZAWSKI (PL) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3294747-A1 | RUTHENIUM COMPLEXES, METHOD OF PRODUCING THEM, AND THEIR USE | Uniwersytet Warszawski (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016092424-A1 | RUTHENIUM COMPLEXES, METHOD OF PRODUCING THEM, AND THEIR USE | UNIWERSYTET WARSZAWSKI (PL) | 2016-06-16 | — | — | WO | disclosed |
| US-9299936-B2 | Organic light-emitting diode including multi-layered hole transporting layer, and flat display device including the organic light-emitting diode | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9257653-B2 | — | — | 2016-02-09 | — | — | US | disclosed |
| WO-2013050437-A1 | HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-11 | — | — | WO | disclosed |
| EP-1740532-A4 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1740532-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | The Regents of the University of California (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005094374-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0680323-B1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS | RHONE POULENC RORER SA (FR) | 1997-04-02 | — | — | EP | disclosed |
| WO-1996019486-A1 | CERTAIN TETRAZOLE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-27 | — | — | WO | disclosed |
| EP-0680323-A1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS. | RHONE POULENC RORER SA (FR) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994016697-A1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS | RHONE-POULENC RORER S.A. (FR) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256677-A1 | HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS | CCNY, NQO2, H1-0 | CHRM1 73/4885NPC1 4210/4885RAB9A 1915/4885 |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CHRM1 3787/4885NPC1 830/4885RAB9A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.